Cargando…
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Immunotherapy has emerged to play a rapidly expanding role in the treatment of cancers. Currently, many clinical trials of therapeutic agents are on ongoing with majority of immune checkpoint inhibitors (ICIs) especially programmed death receptor 1 (PD-1) and its ligand 1 (PD-L1) inhibitors. PD-1 an...
Autores principales: | Ao, Yong-Qiang, Gao, Jian, Wang, Shuai, Jiang, Jia-Hao, Deng, Jie, Wang, Hai-Kun, Xu, Bei, Ding, Jian-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099901/ https://www.ncbi.nlm.nih.gov/pubmed/37055838 http://dx.doi.org/10.1186/s12943-023-01772-4 |
Ejemplares similares
-
Induction Therapy Followed by Surgery for Unresectable Thymic Epithelial Tumours
por: Wang, Shuai, et al.
Publicado: (2022) -
Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1
por: Gao, Jian, et al.
Publicado: (2022) -
Tumor-infiltrating CD36(+)CD8(+)T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer
por: Ao, Yong-Qiang, et al.
Publicado: (2023) -
Comparison between CT and MRI in the Diagnostic Accuracy of Thymic Masses
por: Li, Hao-Ran, et al.
Publicado: (2019) -
Detection of Epstein–Barr virus infection in thymic epithelial tumors by nested PCR and Epstein–Barr-encoded RNA ISH
por: Zhao, Li, et al.
Publicado: (2023)